You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

August 10, 2026

Changes in Nutrition Labeling Requirements in Indonesia

Subscribe to Updates

On June 17, 2026, Indonesia’s National Agency of Drug and Food Control (BPOM) issued BPOM Regulation No. 10 of 2026 on Nutritional Information on Processed Food Labels.

The new regulation, which revokes three previous nutrition labeling regulations, introduces several notable changes affecting food and beverage manufacturers, importers, and distributors. These changes range from updated nutrient reference values and serving-size requirements to the introduction of the Nutri-Level front-of-pack labeling system for certain beverage products. Businesses operating in Indonesia should carefully review these developments and assess their products’ compliance with the new requirements during the transition period.

Implementation of the Nutri-Level Labeling System

To implement the recently issued decree on Nutri-Level labeling, BPOM Regulation No. 10 of 2026 stipulates the requirements to implement the Nutri-Level labeling system on the front-of-pack. Under the new framework, ready-to-drink beverages, powdered beverages, and liquid or solid concentrates are required to display Nutri-Level labeling on the front label of their packaging.

The Nutri-Level labeling system classifies products into color-coded levels A through D based on their sugar, sodium, and total fat content. The applicable Nutri-Level is determined based on the lowest level measured in the assessment of sugar, sodium, and total fat content.

For products classified as level C or D, the Nutri-Level label must be accompanied by information on the relevant sugar, sodium, and total fat content per 100 ml of the ready-to-consume product. Products classified as level A or B may either display only the Nutri-Level designation or display the Nutri-Level together with the relevant nutritional information per 100 ml.

Minimum Vitamin and Mineral Content Required for Declaration

BPOM Regulation No. 10 of 2026 introduces a stricter threshold for the declaration of vitamins and minerals in the nutritional value information section (ING).

Vitamins or minerals may only be declared if they are present at a level of at least 5% of the recommended dietary allowance (RDA) per serving, per 100 g, per 100 ml, or per package, in accordance with the inclusion of the ING table, except for processed foods that declare vitamins or minerals claims in accordance with certain laws and regulations. This represents a significant change from the previous regime under the now-revoked BPOM Regulation No. 26 of 2021, under which vitamins and minerals could be declared when present at a level of at least 2% of the RDA per serving.

Revised Serving Size Requirements

While serving size declarations were already required under BPOM Regulation No. 26 of 2021, BPOM Regulation No. 10 of 2026 introduces additional technical guidance on serving-size determination and presentation. The new regulation expressly requires serving sizes to be rounded to the nearest half-unit, providing a standardized approach to serving-size calculations across product categories. An exception applies to products classified under food category 11.6 (sweeteners, including table-top sweeteners and high-intensity sweeteners), which may require businesses to review and, where necessary, update their existing nutrition labeling.

In addition, an appendix to Regulation No. 10 of 2026 sets out updated serving-size references for a wide range of food categories. As a result, food business operators should review the revised category-specific serving-size references to determine whether their existing nutrition information tables, nutrient calculations, and serving-size declarations remain compliant under the new framework. Although serving-size requirements were already regulated under BPOM Regulation No. 26 of 2021, the 2026 regulation provides greater technical detail and updated references that may necessitate label revisions for certain products.

Updated Nutrient Reference Values

BPOM Regulation No. 10 of 2026 updates the nutrient reference values previously set forth in BPOM Regulation No. 9 of 2016 to correspond with the current development of scientific knowledge in health. Several reference values have been revised from those in BPOM Regulation No. 9 of 2016 (e.g., for total fat, vitamin B1, vitamin B2, vitamin B12, magnesium, potassium, and various other vitamins and minerals). As these values are used to calculate the percentage of RDA displayed in nutrition information tables, the revisions may affect the nutrient percentage calculations currently appearing on product labels.

The regulation also introduces updated nutrient reference methodologies and conversion factors. In particular, vitamin B3 may now be expressed in niacin equivalents (NE), folate may be expressed in dietary folate equivalents (DFE), and revised conversion factors have been adopted for vitamins A, D, and E. These changes are intended to align nutrition labeling requirements with current nutritional science and may require food business operators to reassess existing nutrient declarations and label calculations.

Updated Nutritional Value Information Table Formats

BPOM Regulation No. 10 of 2026 updates the standardized formats for the nutritional value information (ING) table. The regulation continues to allow both vertical and horizontal formats and now provides clearer templates for use on product labels.

For horizontal presentation, businesses may use either a three-column tabular format, which provides more space for displaying nutrient information and additional vitamins or minerals, or a two-column tabular format, which offers a simplified layout suitable for products with limited label space.

 

Three-column per-serving tabular format

 

Two-column per-serving tabular format

 

Three-column per-package tabular format

 

Two-column per-package tabular format

 

BPOM Regulation No. 10 of 2026 also introduces specific flexibility for micro-enterprises regarding the ING table. If analytical results are unavailable and the value of a processed food nutrient has not yet been established by the head of BPOM, the values in the ING table should be declared based on calculation results. The procedure for calculating the nutrient content for processed foods produced by micro-enterprises was established by the head of BPOM in 2026 and involves mostly traditional Indonesian food products.

Transition Period

BPOM Regulation No. 10 of 2026 provides a 24-month transition period to facilitate compliance with the new requirements, so processed foods that had already obtained distribution permits before the regulation entered into force, as well as products that were undergoing registration at that time, must be brought into compliance with the new regulation by June 17, 2028. Similar transitional provisions apply to the implementation of Nutri-Level labeling requirements for affected beverage products. As a result, food business operators are afforded additional time to review product portfolios, update nutritional information, and revise product labels where necessary.

Business Impact

The new regulation will require many food and beverage businesses to review their existing nutrition labeling practices in order to comply with the new requirements. In particular, companies should assess the impact of the revised nutrient reference values, updated serving-size requirements, and Nutri-Level labeling requirements on their products.

The Nutri-Level requirements will be especially relevant for beverage manufacturers. Businesses should therefore begin evaluating their product portfolios and preparing any necessary label updates to ensure compliance before the expiry of the 24-month transition period.

Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

December 30, 2025
The Intellectual Property Office of Vietnam (IP Office), with support from the Japan International Cooperation Agency (JICA), is drafting additional annexes to its Guidelines for Patent Examination, focusing on the examination of patent applications in the pharmaceutical and biotechnology sectors. The new annexes are expected to be officially issued in early 2026 as Annexes III and IV, following the successful issuance in 2023 of Annexes I and II addressing computer program-related inventions. The IP Office recently organized a seminar to gather feedback on the draft annexes from intellectual property representatives, academic institutions, research institutes, and other interested parties, emphasizing its intention to receive further constructive opinions to refine the guidelines for pharmaceuticals and biotechnology. Why These Guidelines Matter Patent examination in Vietnam has traditionally relied on the Guidelines for Patent Examination issued under Decision No. 487/QD-SHTT (2010), recently supplemented by Annexes I and II. While these documents provide a solid foundation, they do not fully address practical challenges in examining pharmaceutical and biotech inventions, particularly issues related to clarity, sufficiency of disclosure, enablement, features of function and utility, combination therapies, and inventions involving artificial intelligence (AI) applications in these fields. Annexes III and IV aim to close these gaps by introducing structured principles and illustrative examples. Guidance on Patent Specification Requirements Annex III provides detailed guidance on the requirements for patent specifications in pharmaceuticals and biotechnology, covering two main parts: Part A addresses sufficiency of disclosure, clarity of specifications, and consistency between claims and descriptions. Part B covers inventions related to Markush-type compounds, claims containing exclusion statements (disclaimers), and additional experimental data submitted during examination. The Guidelines outline specific disclosure requirements for subject matters such as compounds, formulations, pharmaceutical compositions, genes, polypeptides, proteins, vectors, transgenic organisms, modified organisms, and hybrid cells. Annex III emphasizes that disclaimers are not accepted
Read More
November 25, 2025
Food safety incidents can emerge without warning, requiring businesses to act swiftly to protect consumers and comply with regulatory obligations. Across Southeast Asia, Thailand, Vietnam, and Indonesia have each developed comprehensive food recall frameworks designed to ensure rapid removal of unsafe products from the market while holding businesses accountable for compliance failures. While these three jurisdictions share common objectives—protecting public health and ensuring food safety—each has crafted distinct regulatory approaches reflecting their unique administrative structures, enforcement priorities, and legal traditions. Understanding these differences is essential for food businesses operating in the region, as recall procedures, timelines, reporting requirements, and penalties vary significantly across borders. This guide, available through the button below, examines the food recall regulations in Indonesia, Thailand, and Vietnam, providing practical guidance on legal requirements, procedural steps, and compliance obligations in each market.
Read More
October 15, 2025
The Indonesian Food and Drug Administration (BPOM) has introduced more stringent oversight of health supplements containing probiotics with new guidelines that require clinical trials for certain products and expanded documentation standards. BPOM Regulation No. 17 of 2025 replaces the previous 2021 regulation and establishes a comprehensive framework for evaluating probiotic strains used in health supplements. Assessment Requirements The new regulation expands the scope of assessment to include not only categorization and documentation but also technical procedures, strain classification, and clinical trial requirements. Unlike the previous regulation, which provided general guidance, the updated framework creates a comprehensive system for evaluating both registered probiotic strains and new or combined strains. Manufacturers must now submit supporting documentation covering strain identification and functional characterization, safety, efficacy, and product quality. The previous regulation required documentation only on safety, efficacy, and quality. Clinical Trials One of the most significant changes is the requirement for clinical trials conducted in Indonesia for applications that include benefit claims other than maintaining digestive health, or where there are modifications to benefit claims. The regulation specifies that phase 1 trials must demonstrate safety, while phase 2 trials must validate efficacy using statistically valid methods such as double-blind, randomized, placebo-controlled studies). In addition, phase 3 and phase 4 trials may be required, and postmarket surveillance data must be submitted. Technical Assessment Framework Annex 4, a newly introduced section, establishes technical procedures for assessing health supplements containing probiotics in Indonesia. This comprehensive framework outlines criteria for evaluating new probiotic strains, including strain identification, functional characterization, safety, efficacy, and product quality. The annex introduces a clear classification of claims for health supplement products containing probiotics: General claims(e.g., maintaining digestive health). Functional claims(e.g., normal biological function or activity in the body). Risk reduction claims(e.g., lowering disease risk). The regulation restricts use of the term
Read More